⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Official Title: A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab

Study ID: NCT04796194

Study Description

Brief Summary: ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who have either exhausted treatment options or are not eligible for, suitable for, or willing to undergo such treatments.

Detailed Description: The study aims to assess the safety and efficacy of LTX-315 in combination with the immune checkpoint inhibitor (ICI) pembrolizumab in patients with advanced melanoma. LTX-315 has been administered with pembrolizumab in a previous Phase I/II study, and there were clear indications that LTX-315 + pembrolizumab was a clinically active combination. Furthermore, the addition of LTX-315 to pembrolizumab dosing did not appear to increase the overall incidence or severity profile of toxicities. The present study will document the preliminary efficacy, clinical safety, and tolerability of LTX-315 in combination with pembrolizumab, in a dose and regimen that is considered to be safe. Patient population consists of patients with unresectable stage III B, C, D and Stage IVm1a, m1b (without liver mets) metastatic melanoma ECOG performance status of 0 or 1, who have received an FDA-approved anti-PD/PD-L1 therapy and have progressed after prior anti-PD-1 or anti-PD-L1 therapy, alone or in combination with systemic therapy.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Levine Cancer Institute - Atrium Health, Charlotte, North Carolina, United States

University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center, Pittsburgh, Pennsylvania, United States

MD Anderson Cancer Centre, Houston, Texas, United States

Centre Hospitalier Regional Universitaire De Lille, Lille, , France

Gustave Roussy Cancer Campus, Paris, , France

Hospital Lyon Sud, Pierre-Bénite, , France

Akershus University Hospital, Lørenskog, , Norway

Oslo University Hospital--Radiumhospitalet, Oslo, , Norway

Clínica Universidad de Navarra, Pamplona, , Spain

Contact Details

Name: Adi Diab

Affiliation: M.D. Anderson Cancer Center

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: